Jonathan Young
About Jonathan Young
Jonathan Young is the Executive Vice President and COO of Akero Therapeutics, where he has worked since 2018. He has extensive experience in biotechnology, law, and policy, having held leadership roles in various organizations, including serving as the Founding President and CEO of Akero Therapeutics and as Chairman of the National Council on Disability.
Work at Akero Therapeutics
Jonathan Young currently holds the position of Executive Vice President and COO at Akero Therapeutics, a role he has occupied since 2018. He previously served as the Founding President and CEO of the company from 2017 to 2018. His leadership has been instrumental in the company's development and strategic direction in the biotechnology sector, particularly in drug development.
Education and Expertise
Jonathan Young has an extensive educational background. He earned a Bachelor of Arts in History from Messiah University, followed by a Ph.D. and M.A. in American History from the University of North Carolina at Chapel Hill. He also holds a Juris Doctor (J.D.) from Yale Law School. His academic achievements complement his diversified leadership experience in biotechnology, law, and policy.
Background
Young has a diverse professional history, having worked in various capacities across private industry, government, and nonprofit sectors. He served as General Counsel and Vice President of Policy at Braeburn Pharmaceuticals and was a Partner and General Counsel at FoxKiser. Additionally, he was a Venture Partner at Apple Tree Partners and coordinated disability policy for the White House during President Bill Clinton's administration.
Achievements
Jonathan Young has been recognized for his contributions to disability advocacy. He was appointed by President Barack Obama as Chairman of the National Council on Disability, where he focused on policies that empower patients and individuals with disabilities. He also serves on the board of directors of the MedStar Health Research Institute, further demonstrating his commitment to health policy and patient advocacy.